Myocarditis (Cardiovascular) - Drugs In Development, 2021

June 2021 | 57 pages | ID: M1A3288A251FEN
Global Markets Direct

Abstracts

Myocarditis (Cardiovascular) - Drugs In Development, 2021

SUMMARY

Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Myocarditis (Cardiovascular) - Drugs In Development, 2021, provides an overview of the Myocarditis (Cardiovascular) pipeline landscape.

Myocarditis is inflammation of the heart muscle. Myocarditis is an uncommon disorder that is usually caused by viral, bacterial, or fungal infections that reach the heart. Symptoms include chest pain, rapid or abnormal heartbeat, shortness of breath, at rest or during physical activity, fluid retention with swelling of legs, ankles and feet and fatigue. Treatment includes antibiotics, anti-inflammatory medicines to reduce swelling and diuretics to remove excess water from the body.

REPORT HIGHLIGHTS

Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Myocarditis (Cardiovascular) - Drugs In Development, 2021, provides comprehensive information on the therapeutics under development for Myocarditis (Cardiovascular), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Myocarditis (Cardiovascular) pipeline guide also reviews of key players involved in therapeutic development for Myocarditis and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Phase III, Phase I, Preclinical and Discovery stages are 1, 1, 2 and 2 respectively. Similarly, the Universities portfolio in Preclinical stages comprises 1 molecules, respectively.

Myocarditis (Cardiovascular) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

SCOPE

• The pipeline guide provides a snapshot of the global therapeutic landscape of Myocarditis (Cardiovascular).
• The pipeline guide reviews pipeline therapeutics for Myocarditis (Cardiovascular) by companies and universities/research institutes based on information derived from company and industry-specific sources.
• The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
• The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
• The pipeline guide reviews key companies involved in Myocarditis (Cardiovascular) therapeutics and enlists all their major and minor projects.
• The pipeline guide evaluates Myocarditis (Cardiovascular) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
• The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
• The pipeline guide reviews latest news related to pipeline therapeutics for Myocarditis (Cardiovascular)

REASONS TO BUY

• Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
• Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
• Find and recognize significant and varied types of therapeutics under development for Myocarditis (Cardiovascular).
• Classify potential new clients or partners in the target demographic.
• Develop tactical initiatives by understanding the focus areas of leading companies.
• Plan mergers and acquisitions meritoriously by identifying key players and it’s most promising pipeline therapeutics.
• Formulate corrective measures for pipeline projects by understanding Myocarditis (Cardiovascular) pipeline depth and focus of Indication therapeutics.
• Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
• Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.

Contents

Introduction
Global Markets Direct Report Coverage
Myocarditis - Overview
Myocarditis - Therapeutics Development
Pipeline Overview
Pipeline by Companies
Pipeline by Universities/Institutes
Products under Development by Companies
Products under Development by Universities/Institutes
Myocarditis - Therapeutics Assessment
Assessment by Target
Assessment by Mechanism of Action
Assessment by Route of Administration
Assessment by Molecule Type
Myocarditis - Companies Involved in Therapeutics Development
Apitope International NV
Cantargia AB
Cardiol Therapeutics Inc
Dynomics Inc
Evotec SE
Swedish Orphan Biovitrum AB
Myocarditis - Drug Profiles
anakinra - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
ATX-MYO - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
CAN-10 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
cannabidiol 1 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
coxsackievirus B (hexavalent) vaccine - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
DYN-502 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Recombinant Peptides for Myocardial Infarction and Myocarditis - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Myocarditis - Dormant Projects
Myocarditis - Product Development Milestones
Featured News & Press Releases
May 10, 2021: Cantargia presents new preclinical data showing unique improvement of heart function in myocarditis using antibody CAN10
Apr 28, 2021: Cardiol Therapeutics announces first patient enrolled in LANCER, a Phase II/III outcomes trial in high-risk patients hospitalized with COVID-19
Apr 26, 2021: Cantargia presents new preclinical data on antibody CAN10 at IMMMUNOLOGY2021
Apr 12, 2021: Cardiol Therapeutics announces topline results from phase I single and multiple ascending dose clinical trial of CardiolRx
Mar 19, 2021: Cantargia reports positive preclinical safety and efficacy results in the CAN10 project
Dec 22, 2020: Cardiol Therapeutics announces completion of phase I clinical study of CardiolRx
Nov 27, 2020: BioInvent signs monoclonal antibody manufacturing deal with Cantargia
Aug 26, 2020: Cardiol Therapeutics initiates Health Canada approved Phase 1 clinical study of CardiolRx
Apr 07, 2020: Cantargia provides update on development project CAN10
Apr 05, 2020: Cardiol Therapeutics receives Health Canada approval for phase 1 study of its pharmaceutically produced cannabidiol (CBD) formulation
Apr 01, 2020: Cardiol Therapeutics announces study results confirm the cardioprotective role of its pharmaceutical cannabidiol formulation in a model of heart failure
Dec 05, 2019: Cantargia selects CAN10 as development project in systemic sclerosis and myocarditis
Nov 25, 2019: Cardiol Therapeutics comments on the descheduling of Purisys Cannabinoid ingredients by U.S. Drug Enforcement Agency
Nov 19, 2019: Cardiol Therapeutics announces clinical steering committee for phase 2 international trial in Acute Myocarditis using CardiolRx 100
Oct 01, 2019: Cardiol Therapeutics announces completion of manufacturing scale-up for commercialization of CardiolRx 100
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer

List Of Tables

LIST OF TABLES

Number of Products under Development for Myocarditis, 2021
Number of Products under Development by Companies, 2021
Number of Products under Development by Universities/Institutes, 2021
Products under Development by Companies, 2021
Products under Development by Universities/Institutes, 2021
Number of Products by Stage and Target, 2021
Number of Products by Stage and Mechanism of Action, 2021
Number of Products by Stage and Route of Administration, 2021
Number of Products by Stage and Molecule Type, 2021
Myocarditis - Pipeline by Apitope International NV, 2021
Myocarditis - Pipeline by Cantargia AB, 2021
Myocarditis - Pipeline by Cardiol Therapeutics Inc, 2021
Myocarditis - Pipeline by Dynomics Inc, 2021
Myocarditis - Pipeline by Evotec SE, 2021
Myocarditis - Pipeline by Swedish Orphan Biovitrum AB, 2021
Myocarditis - Dormant Projects, 2021

List Of Figures

LIST OF FIGURES

Number of Products under Development for Myocarditis, 2021
Number of Products under Development by Companies, 2021
Number of Products by Targets, 2021
Number of Products by Stage and Targets, 2021
Number of Products by Mechanism of Actions, 2021
Number of Products by Stage and Top 10 Mechanism of Actions, 2021
Number of Products by Routes of Administration, 2021
Number of Products by Stage and Routes of Administration, 2021
Number of Products by Molecule Types, 2021
Number of Products by Stage and Molecule Types, 2021